Aptevo Therapeutics Inc. (APVO)
Company Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40.
It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer.
The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Country | United States |
| IPO Date | Jul 20, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Marvin L. White |
Contact Details
Address: 2401 4th Avenue Seattle, Washington United States | |
| Website | https://www.aptevotherapeutics.com |
Stock Details
| Ticker Symbol | APVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671584 |
| CUSIP Number | 03835L207 |
| ISIN Number | US03835L2079 |
| Employer ID | 81-1567056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. White | President, Chief Executive Officer & Director |
| Jeffrey G. Lamothe CA | Executive Vice President & Chief Operating Officer |
| Dr. Dirk Huebner M.D. | Chief Medical Officer |
| SoYoung Kwon J.D., LL.M. | Corporate Secretary, Senior Vice President, General Counsel, Business Development & Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 424B5 | Filing |
| Apr 28, 2025 | 424B4 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 25, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 424B4 | Filing |